Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS MONTH'S ISSUE:
February 2017

Mood Stabilizers during Pregnancy: Clinical Updates
Based on current data of in utero exposure to mood stabilizers, valproic acid (Depakene, Depakote, and others) and carbamazepine (Tegretol and others) present the greatest risk for adverse long-term neurobehavioral outcomes, whereas lithium and lamotrigine (Lamictal and others) so far appear to be safe. Antipsychotics have not been adequately studied.

Ongoing Treatment for BDD
Of patients with body dysmorphic disorder who respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), those who are continued on SSRI treatment for 6 months show greater improvement and longer time to relapse than those switched to placebo.

In Brief
FDA Removes Black Box Warning for Smoking Cessation Drugs Varenicline and Bupropion; Low Levels of Brain-Derived Neurotrophic Factor Decrease Depressed Patients Response to Chemotherapy

Antihypertensives and the Risk of Mood Disorders
In a Scottish retrospective study, patients who took angiotensin antagonist antihypertensive medications had a lower risk of being admitted to the hospital for a mood disorder than those who did not.

Affiliated Links

The Journal of Clinical Psychiatry

The University of Arizona Health Sciences Center- Department of Psychiatry

American Academy of Child and Adolescent Psychiatry

American Association of Suicidology

American Psychiatric Association

American Society for Adolescent Psychiatry

American Society of Addiction Medicine

American Society of Clinical Psychopharmacology

Autism Society of America

Depression and Bipolar Support Alliance (DBSA)

National Alliance for Research on Schizophrenia and Depression (NARSAD)

National Alliance for the Mentally Ill

National Association of Alcoholism and Drug Abuse Counselors

National Institute of Mental Health

National Mental Health Association